News | November 13, 2014

Coquí RadioPharmaceuticals Will Build First U.S. Production Facility

The facility will be producing Molybdenum-99, the parent isotope of Technetium-99, the isotope used in 80% of nuclear medicine procedures

 Nov. 13. 2014 — Coquí RadioPharmaceuticals Corp. (Coquí Pharma) is working to become the first commercial producer of lifesaving medical isotopes in the United States.  In 2012, Congress passed legislation making it a national priority to produce Molybdenum-99, an isotope necessary to detect a wide range of diseases, including cardiovascular disease and cancer.

“Among the aspiring medical isotope production companies looking to build facilities in the U.S., Coquí Pharma is the only one using a design and production method already demonstrated throughout the world as safe, efficient and reliable,” stated Carmen Bigles, CEO of Coquí.  Coquí Pharma recently announced their plans to construct the medical isotope production facility at the Sid Martin Biotechnology Incubator in Progress Corporate Park, Alachua, Florida.

The facility will be producing Molybdenum-99, the parent isotope of Technetium-99, the isotope used in 80% of nuclear medicine procedures. Once operational, Coquí Pharma will be capable of supplying a large portion of the U.S. market and, ultimately, the international.

International production sources tend to be older and unreliable, which can delay delivery of potentially life-saving medical diagnostics and treatments to patients.  International facilities also tend to use highly enriched uranium, which can raise proliferation concerns. Coquí has selected INVAP, an internationally recognized Argentinian firm to design and construct the proposed facility. 

INVAP has designed and constructed a number of similar facilities around the world, including the OPAL research reactor in Australia, the RA-3 in Argentina, and other facilities that are successfully producing Mo-99 with low enriched uranium.

For more information: www.coquipharma.com

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init